Showing 1-10 of 27 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Intrinsic Tolerance in GINS: Dissecting the HVEM/BTLA Axis Driving Hypoimmunogenicity | Weill Medical College of Cornell University | Anna Ada Dattoli | Cures | 01-April-2026 to 31-March-2027 | $199.999,32 |
| Determining the role of SSTR2 on PRL-2903-mediated glucagon secretion | Trustees of Columbia University in the City of New York | Xiaojuan Chen | Improving Lives | 01-April-2026 to 31-March-2027 | $199.999,39 |
| Protective Interventions against Loss of Function and Destruction of β cells in Type 1 Diabetes. | Icahn School of Medicine at Mount Sinai | Romina Bevacqua | Cures | 01-March-2026 to 28-February-2031 | $999.999,00 |
| Chemical Perturb-seq to identify small molecules controlling the maturation and survival on human beta cells | Weill Medical College of Cornell University | Xiaoshan Zhang | Cures | 01-March-2026 to 28-February-2029 | $256.285,00 |
| Stromal Cell Targeted Tolerogenic mRNA Therapy for T1D | Endotope Biosciences | Raymond Liang | Cures | 15-December-2025 to — | $550.417,82 |
| Project Tuyinza | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-April-2026 to 31-March-2029 | $643.550,00 |
| Collaboration for Global T1D Care | Acora | Rebecca Goldman | Mission | 01-December-2025 to 31-January-2027 | $648.500,00 |
| Enhancing Functional Maturation of Stem Cell-Derived Beta Cells Using Harmine for Improved Diabetes Therapy | Icahn School of Medicine at Mount Sinai | Peng Wang | Cures | 01-July-2025 to 30-June-2026 | $305.000,00 |
| Project Equity | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-May-2024 to 30-April-2026 | $333.172,00 |
| Market Analysis of Insulin Products Utilized by Patients With T1D & Pervasiveness of Insulin Caps | Milliman | Rebecca Smith | Transportfolio | 01-January-2025 to 31-December-2025 | $590.000,00 |